Back to News
Market Impact: 0.28
Centene Reaffirms 2026 EPS Outlook as Medicaid Membership Decline Deepens
Source: marketbeat.com
Corporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Centene reaffirmed its 2026 adjusted diluted EPS guidance of more than $4.80. CEO Sarah London said performance during the first two months of the third quarter was in line with expectations, signaling no deterioration in the company’s outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.22
Ticker Sentiment
CNC0.42
More News
- Should You Buy SpaceX Stock Before Its Next Earnings Report?
- Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
- Who’s who in Fed’s September 2026 dot plot?
- Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
- China slows humanoid robot IPO rush as hype outruns reality
- Porsche could face another 4,000 job cuts, Handelsblatt reports